Interacting Drugs |
Deferasirox vs CYP2C8 Substrates (High risk) |
Security Level |
|
Mechanism |
CYP2C8 Substrates (High risk): Deferasirox may increase the serum concentration of CYP2C8 Substrates (High risk). |
Management |
Monitor therapy |
Deferasirox vs CYP2C8 Substrates (High risk)
Post Review about Deferasirox vs CYP2C8 Substrates (High risk) Click here to cancel reply.
Other Interactions of Deferasirox
Other Interactions of CYP2C8 Substrates (High risk)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.